190 related articles for article (PubMed ID: 25087721)
1. α-Keto phenylamides as P1'-extended proteasome inhibitors.
Voss C; Scholz C; Knorr S; Beck P; Stein ML; Zall A; Kuckelkorn U; Kloetzel PM; Groll M; Hamacher K; Schmidt B
ChemMedChem; 2014 Nov; 9(11):2557-64. PubMed ID: 25087721
[TBL] [Abstract][Full Text] [Related]
2. A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
Wang J; Liang B; Chen Y; Fuk-Woo Chan J; Yuan S; Ye H; Nie L; Zhou J; Wu Y; Wu M; Huang LS; An J; Warshel A; Yuen KY; Ciechanover A; Huang Z; Xu Y
Eur J Med Chem; 2021 Apr; 215():113267. PubMed ID: 33639344
[TBL] [Abstract][Full Text] [Related]
3. Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes.
Ettari R; Cerchia C; Maiorana S; Guccione M; Novellino E; Bitto A; Grasso S; Lavecchia A; Zappalà M
ChemMedChem; 2019 Apr; 14(8):842-852. PubMed ID: 30829448
[TBL] [Abstract][Full Text] [Related]
4. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
5. C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome.
Hovhannisyan A; Pham TH; Bouvier D; Qin L; Melikyan G; Reboud-Ravaux M; Bouvier-Durand M
Bioorg Med Chem Lett; 2013 May; 23(9):2696-703. PubMed ID: 23541650
[TBL] [Abstract][Full Text] [Related]
6. Cell-Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit.
Stubba D; Bensinger D; Steinbacher J; Proskurjakov L; Salcedo Gómez Á; Schmidt U; Roth S; Schmitz K; Schmidt B
ChemMedChem; 2019 Dec; 14(23):2005-2022. PubMed ID: 31675179
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
[TBL] [Abstract][Full Text] [Related]
8. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits.
Hovhannisyan AA; Pham TH; Bouvier D; Tan X; Touhar S; Mkryan GG; Dallakyan AM; El Amri C; Melikyan GS; Reboud-Ravaux M; Bouvier-Durand M
Bioorg Med Chem Lett; 2017 Dec; 27(23):5172-5178. PubMed ID: 29113763
[TBL] [Abstract][Full Text] [Related]
9. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
[TBL] [Abstract][Full Text] [Related]
10. A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor.
Hasegawa M; Yasuda Y; Tanaka M; Nakata K; Umeda E; Wang Y; Watanabe C; Uetake S; Kunoh T; Shionyu M; Sasaki R; Shiina I; Mizukami T
Eur J Med Chem; 2014 Jan; 71():290-305. PubMed ID: 24321833
[TBL] [Abstract][Full Text] [Related]
11. Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones.
Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
Bioorg Med Chem; 2014 Jun; 22(12):3091-5. PubMed ID: 24814885
[TBL] [Abstract][Full Text] [Related]
12. 1,2,4-Oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome.
Maréchal X; Genin E; Qin L; Sperandio O; Montes M; Basse N; Richy N; Miteva MA; Reboud-Ravaux M; Vidal J; Villoutreix BO
Curr Med Chem; 2013; 20(18):2351-62. PubMed ID: 23531222
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
14. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
[TBL] [Abstract][Full Text] [Related]
15. Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif.
Stein ML; Cui H; Beck P; Dubiella C; Voss C; Krüger A; Schmidt B; Groll M
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1679-83. PubMed ID: 24403024
[TBL] [Abstract][Full Text] [Related]
16. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
[TBL] [Abstract][Full Text] [Related]
17. [Design, synthesis and biological assay of novel tripeptidic tetrazoles as inhibitors of 20S proteasome].
Ma YH; Xu B; Cui JR; Yang ZJ; Zhang LR; Zhang LH
Yao Xue Xue Bao; 2012 Apr; 47(4):472-8. PubMed ID: 22799029
[TBL] [Abstract][Full Text] [Related]
18. Identification of a new series of amides as non-covalent proteasome inhibitors.
Scarbaci K; Troiano V; Micale N; Ettari R; Tamborini L; Di Giovanni C; Cerchia C; Grasso S; Novellino E; Schirmeister T; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Apr; 76():1-9. PubMed ID: 24561716
[TBL] [Abstract][Full Text] [Related]
19. Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors.
Huber EM; de Bruin G; Heinemeyer W; Paniagua Soriano G; Overkleeft HS; Groll M
J Am Chem Soc; 2015 Jun; 137(24):7835-42. PubMed ID: 26020686
[TBL] [Abstract][Full Text] [Related]
20. New C(4)- and C(1)-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform.
Hovhannisyan A; Pham TH; Bouvier D; Piroyan A; Dufau L; Qin L; Cheng Y; Melikyan G; Reboud-Ravaux M; Bouvier-Durand M
Bioorg Med Chem Lett; 2014 Mar; 24(6):1571-80. PubMed ID: 24534487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
